Je was op zoek naar: studiedesign (Deens - Engels)

studiedesign
study design

studiedesign (region)
study design (region)

resumé af studiedesign
summary of study design

tabel 2: studiedesign
table 2: study design

studiedesign og baseline-karakteristika er vist i tabel 3.
the study designs and baseline characteristics are presented in table 3.

tabel 2: studiedesign og baseline-karakteristika for studie 1 og 2
table 2: study design and baseline characteristics for studies 1 and 2

studiedesign/demografi og resultater for studie 1 og 2 fremgår af henholdsvis tabel 2 og 3.
for studies 1 and 2, study design/demographics and results are shown in table 2 and table 3 respectively.

tabel 11: studier udført med simeprevir + sofosbuvir: population og resumé af studiedesign
table 11: studies conducted with simeprevir + sofosbuvir: population and summary of study design

det overordnede studiedesign var identisk i begge stadier, og patienterne blev randomiseret til en af følgende to behandlingsgrupper:
the overall trial design was identical among both stages and patients were randomized into the following two treatment groups:

tabel 3: studiedesign og baseline-karakteristika for select-studiet og decide-studiet
table 3: study design and baseline characteristics for select study and decide study

i henhold til studiedesign kan patienterne i langtids- opfølgningsperioden have skiftet mellem doserne 50 mg og 100 mg simponi efter studielægens skøn.
by study design, patients in the long-term extension may have switched between the 50 mg and 100 mg simponi doses at the discretion of the study physician.

som det var forventet på basis af studiedesignet, sås ingen forskel i varighed af remission, sygdomsfri overlevelse eller generel overlevelse, skønt patienter med komplet molekylær respons og forblivende i minimal residual sygdom havde større udbytte af behandlingen i form af både varighed af remission (p = 0,01) og sygdomsfri overlevelse (p = 0,02).
as expected on the basis of the study design, no difference was observed in remission duration, disease-free survival or overall survival, although patients with complete molecular response and remaining in minimal residual disease had a better outcome in terms of both remission duration (p = 0.01) and disease-free survival (p = 0.02).